1. Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial. Issue 9 (September 2020) Authors: Diefenbach, Catherine S; Hong, Fangxin; Ambinder, Richard F; Cohen, Jonathon B; Robertson, Michael J; David, Kevin A; Advani, Ranjana H; Fenske, Timothy S; Barta, Stefan K; Palmisiano, Neil D; Svoboda, Jakub; Morgan, David S; Karmali, Reem; Sharon, Elad; Streicher, Howard; Kahl, Brad S; Ansell, S... Journal: Lancet Issue: Volume 7:Issue 9(2020) Page Start: e660 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗